Cortexyme announces european screening now underway in the phase 2/3 gain trial
Cortexyme, inc. announced the start of screening in europe for the gain (gingipain inhibitor for treatment of alzheimer’s disease) trial, the company’s ongoing phase 2/3 clinical study of lead investigational medicine cor388 in subjects with mild to moderate alzheimer’s disease (ad). the international trial has been enrolling in the united states since the second quarter of 2019 and is targeting enrollment of approximately 570 subjects. the gain trial is based on the growing body of scienti?c evidence that the bacterium most commonly associated with chronic periodontal disease, porphyromonas gingivalis plays a key role in the development of ad, given its identification in the brains of ad patients and ability to cause neurodegeneration, inflammation, and other pathology associated with alzheimer’s in animal models. the trial evaluates the ability of cor388, an investigational medicine designed to inactivate the toxic proteases, or gingipains, released by the bacteria, to stop or slow further damage to brain cells. prior clinical studies of cor388 showed the compound was well-tolerated and identified positive trends across biomarkers and cognitive tests in subjects with ad.
QNCX Ratings Summary
QNCX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission